Gemcitabine plus docetaxel “may serve as a reasonable alternative first-line therapy for patients with high-risk NMIBC during the ongoing BCG shortage,” according to researchers.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
A protocol for eliminating routine opioid prescription after major urologic cancer surgery was both safe and successful, according to researchers.
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
A high pretreatment neutrophil-to-lymphocyte ratio is associated with worse outcomes in patients with muscle-invasive bladder cancer, a study suggests.
A survey of US urologic oncologists suggests that reproductive organ-sparing and nerve-sparing radical cystectomy may be underused in women with bladder cancer.
A 74-year-old man presents to the oncology infusion center 1 week after receiving an intravenous dose of enfortumab vedotin-ejfv. His right arm has a large erythema and blister. Can you make the correct diagnosis?
Incidence and mortality rates for major genitourinary cancers differ according to sex, race/ethnicity, and geographic region.
A systematic review evaluated current and investigational intravesical and systemic therapies for NMIBC after BCG failure, including chemotherapy, immunotherapy, combination therapy, hyperthermia, and novel biologic agents.
